Amer M Zeidan

Amer M Zeidan

UNVERIFIED PROFILE

Are you Amer M Zeidan?   Register this Author

Register author
Amer M Zeidan

Amer M Zeidan

Publications by authors named "Amer M Zeidan"

Are you Amer M Zeidan?   Register this Author

100Publications

1527Reads

11Profile Views

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.

Blood Rev 2019 Jul 29;36:70-87. Epub 2019 Apr 29.

Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, USA; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183013
Publisher Site
http://dx.doi.org/10.1016/j.blre.2019.04.005DOI Listing
July 2019

Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?

Leuk Lymphoma 2019 Jun 17;60(6):1354-1369. Epub 2019 Jan 17.

a Section of Hematology, Department of Internal Medicine , Yale University School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1546854DOI Listing
June 2019

Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.

Leukemia 2019 Jun 8;33(6):1303-1312. Epub 2019 Apr 8.

Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0448-2DOI Listing
June 2019

Healthcare expenses for treatment of acute myeloid leukemia.

Expert Rev Hematol 2019 Jun 13:1-10. Epub 2019 Jun 13.

a Department of Internal Medicine, School of Medicine , Yale University , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1627869DOI Listing
June 2019

RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.

Leuk Lymphoma 2019 Jun 7:1-7. Epub 2019 Jun 7.

b Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center , Yale University , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1622700DOI Listing
June 2019

Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?

Cancer 2019 May 12;125(9):1410-1413. Epub 2019 Mar 12.

Section of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467744PMC
May 2019

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Expert Rev Anticancer Ther 2019 May 19;19(5):393-404. Epub 2019 Mar 19.

a Department of Internal Medicine, Section of Hematology , Yale University School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737140.2019.1
Publisher Site
http://dx.doi.org/10.1080/14737140.2019.1589374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527485PMC
May 2019

Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations.

Leuk Lymphoma 2019 Apr 3:1-4. Epub 2019 Apr 3.

a Division of Hematology, Department of Medicine , Yale University School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1594221DOI Listing
April 2019

Getting personal with myelodysplastic syndromes: is now the right time?

Expert Rev Hematol 2019 Apr 12;12(4):215-224. Epub 2019 Apr 12.

a Section of Hematology, Department of Internal Medicine , Yale University School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1592673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540985PMC
April 2019

Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Department of Internal Medicine, Section of Hematology, Yale School of Medicine;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.219345DOI Listing
April 2019

Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.

Blood Rev 2019 03 21;34:1-15. Epub 2018 Sep 21.

Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, USA; Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.09.001DOI Listing
March 2019

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

Blood Rev 2019 03 5;34:67-83. Epub 2018 Dec 5.

Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183007
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.12.001DOI Listing
March 2019

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.

J Natl Compr Canc Netw 2019 Mar;17(3):211-219

bDepartment of Chronic Disease Epidemiology, Yale School of Public Health.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7095DOI Listing
March 2019

Myeloid disorders after autoimmune disease.

Best Pract Res Clin Haematol 2019 03 7;32(1):74-88. Epub 2019 Feb 7.

Yale University School of Medicine, Department of Medicine, Section of Hematology, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2019.02.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541412PMC
March 2019

Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.

Ann Hematol 2019 Jan 19;98(1):237-240. Epub 2018 Jul 19.

Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, Yale University School of Medicine, New Haven, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3427-1DOI Listing
January 2019

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

Ther Adv Hematol 2019 11;10:2040620718816698. Epub 2019 Jan 11.

Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8055, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620718816698DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348528PMC
January 2019

Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts.

Eur J Haematol 2018 Dec 10;101(6):711-720. Epub 2018 Oct 10.

Division of Hematology/Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13153DOI Listing
December 2018

Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice.

Ann Hematol 2018 Dec 14;97(12):2333-2343. Epub 2018 Aug 14.

Division of Hematology/Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3474-7DOI Listing
December 2018

Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.

Ann Hematol 2018 11 7;97(11):2245-2248. Epub 2018 Aug 7.

Division of Hematology/Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3459-6DOI Listing
November 2018

Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.

Cancer 2018 Nov 14;124(21):4211-4220. Epub 2018 Sep 14.

Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263848PMC
November 2018

Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?

Leuk Lymphoma 2018 09 7;59(9):2015-2017. Epub 2018 Feb 7.

a Department of Internal Medicine School of Medicine , Yale University , New Haven , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1430797DOI Listing
September 2018

To chelate or not to chelate in MDS: That is the question!

Blood Rev 2018 09 8;32(5):368-377. Epub 2018 Mar 8.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.03.002DOI Listing
September 2018

The genetic and molecular pathogenesis of myelodysplastic syndromes.

Eur J Haematol 2018 Sep 12;101(3):260-271. Epub 2018 Jul 12.

Division of Hematology/Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13092DOI Listing
September 2018

Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.

Expert Rev Hematol 2018 09 22;11(9):715-726. Epub 2018 Aug 22.

a Division of Hematology/Medical Oncology, Department of Medicine , Yale University School of Medicine , New Haven , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1503049DOI Listing
September 2018

The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.

Am J Hematol 2018 07 28;93(7):943-952. Epub 2018 Apr 28.

Harvard Medical School, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25103DOI Listing
July 2018

Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?

Authors:
Amer M Zeidan

Leuk Lymphoma 2018 05 27;59(5):1030-1032. Epub 2017 Sep 27.

a Department of Internal Medicine, School of Medicine , Yale University , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1382700DOI Listing
May 2018

Improved JAK Inhibition in Myelofibrosis-The Long Road Ahead.

JAMA Oncol 2018 May;4(5):659-660

Section of Hematology, Department of Internal Medicine, Yale University, and the Yale Cancer Center, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.5802DOI Listing
May 2018

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

J Blood Med 2018 13;9:67-74. Epub 2018 Apr 13.

Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JBM.S136575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908210PMC
April 2018

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Blood 2018 02 19;131(7):818-821. Epub 2017 Dec 19.

Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-10-811729DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410557PMC
February 2018

The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies.

Blood Rev 2017 11 14;31(6):370-388. Epub 2017 Jul 14.

Department of Dermatology, Yale School of Medicine, New Haven, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2017.07.003DOI Listing
November 2017

Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.

Cancer 2017 Oct 22;123(19):3763-3771. Epub 2017 Jun 22.

Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30818DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610636PMC
October 2017

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Cancer 2017 Oct 31;123(19):3662-3672. Epub 2017 Jul 31.

Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30903DOI Listing
October 2017

Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.

J Clin Oncol 2017 Oct 7;35(30):3417-3424. Epub 2017 Aug 7.

Rong Wang, Amy J. Davidoff, and Xiaomei Ma, Yale School of Public Health; Rong Wang, Amer M. Zeidan, Xiao Xu, Amy J. Davidoff, Scott F. Huntington, Cary P. Gross, and Xiaomei Ma, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center; Amer M. Zeidan, Stephanie Halene, Xiao Xu, Scott F. Huntington, Nikolai A. Podoltsev, Cary P. Gross, and Steven D. Gore, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.7149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648174PMC
October 2017

US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box.

J Clin Oncol 2017 10 8;35(28):3264. Epub 2017 Aug 8.

Amer M. Zeidan, Steven D. Gore, and Amy J. Davidoff, Yale University, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3104DOI Listing
October 2017

Risk stratification in therapy-related myelodysplastic syndromes.

Authors:
Amer M Zeidan

Oncotarget 2017 Oct 24;8(46):80103-80104. Epub 2017 Sep 24.

Section of Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655180PMC
October 2017

Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.

Crit Rev Oncol Hematol 2017 Sep 12;117:57-66. Epub 2017 Jul 12.

Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.07.002DOI Listing
September 2017

Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Target Oncol 2017 08;12(4):413-447

Department of Internal Medicine, Section of Hematology, Yale School of Medicine, 300 George Street, New Haven, CT, 06510-3222, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-017-0503-8DOI Listing
August 2017

Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.

Ann Hematol 2017 06 20;96(6):1037-1039. Epub 2017 Feb 20.

Department of Dermatology, Yale School of Medicine, 333 Cedar St, LCI 501, PO Box 208059, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-2954-5DOI Listing
June 2017

Therapy-related myelodysplastic syndromes, or are they?

Blood Rev 2017 05 24;31(3):119-128. Epub 2016 Nov 24.

Section of Hematology, Department of Medicine, Yale University, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X163011
Publisher Site
http://dx.doi.org/10.1016/j.blre.2016.11.002DOI Listing
May 2017

Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

Cancer 2017 05 17;123(6):911-914. Epub 2017 Jan 17.

Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30532DOI Listing
May 2017

Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.

Cancer 2017 05 13;123(10):1703-1713. Epub 2017 Feb 13.

Section of Hematology, Department of Internal Medicine Yale University, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30585DOI Listing
May 2017

Management of myelofibrosis: JAK inhibition and beyond.

Expert Rev Hematol 2017 05 26;10(5):459-477. Epub 2017 Apr 26.

a Yale University School of Medicine , Department of Internal Medicine, Section of Hematology and the Yale Cancer Center , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1317590DOI Listing
May 2017

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.

Leuk Lymphoma 2017 04 25;58(4):982-985. Epub 2016 Aug 25.

b Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center , Yale University , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1214954DOI Listing
April 2017

Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.

Prostate 2017 04 21;77(5):437-445. Epub 2016 Nov 21.

Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785924PMC
April 2017

Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.

Expert Rev Hematol 2017 Apr 9;10(4):345-364. Epub 2017 Mar 9.

a Section of Hematology, Department of Internal Medicine, Section of Hematology, Yale University and the Yale Comprehensive Cancer Center , Yale University School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1297704DOI Listing
April 2017

The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions.

Curr Diabetes Rev 2016 ;12(3):231-9

Section of Hematology, Department of Internal Medicine, Yale University, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028.

View Article

Download full-text PDF

Source
March 2017

Selecting initial treatment of acute myeloid leukaemia in older adults.

Blood Rev 2017 03 8;31(2):43-62. Epub 2016 Oct 8.

Department of Internal Medicine, Hematology Section, Yale University School of Medicine, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2016.09.005DOI Listing
March 2017

The importance of erythroblast enumeration in myeloid neoplasia.

Ann Hematol 2017 Feb 23;96(2):329-330. Epub 2016 Oct 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2862-0DOI Listing
February 2017

Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016.

Leuk Res 2017 02 24;53:8-12. Epub 2016 Nov 24.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.11.011DOI Listing
February 2017

New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.

Expert Rev Hematol 2016 15;9(4):377-88. Epub 2016 Feb 15.

d Division of Hematology, Department of Medicine , Yale University , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2016.1135047DOI Listing
December 2016

Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.

Br J Haematol 2016 Dec 21;175(5):829-840. Epub 2016 Sep 21.

Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14305DOI Listing
December 2016

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.

Ann Hematol 2016 Oct 29;95(11):1895-8. Epub 2016 Jul 29.

Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-016-2761-4
Publisher Site
http://dx.doi.org/10.1007/s00277-016-2761-4DOI Listing
October 2016

Epigenetics in Cancer: A Hematological Perspective.

PLoS Genet 2016 Oct 10;12(10):e1006193. Epub 2016 Oct 10.

Department of Internal Medicine, Section of Hematology, Yale Cancer Center at Yale University, New Haven, Connecticut, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pgen.1006193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065123PMC
October 2016

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities.

World J Stem Cells 2016 Oct;8(10):316-331

Maximilian Stahl, Tae Kon Kim, Amer M Zeidan, Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510-3222, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4252/wjsc.v8.i10.316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080639PMC
October 2016

Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

Medicare Medicaid Res Rev 2014 26;4(4). Epub 2014 Nov 26.

University of Maryland, School of Medicine-Greenebaum Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5600/mmrr.004.04.a02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254334PMC
September 2016

Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?

Blood Rev 2016 09 25;30(5):381-8. Epub 2016 Apr 25.

Section of Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X163001
Publisher Site
http://dx.doi.org/10.1016/j.blre.2016.04.006DOI Listing
September 2016

Emerging biological therapies for the treatment of myelodysplastic syndromes.

Expert Opin Emerg Drugs 2016 Sep 19;21(3):283-300. Epub 2016 Aug 19.

c Oncologic Sciences , University of South Florida College of Medicine , Tampa , Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2016.1220534DOI Listing
September 2016

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.

Ann Hematol 2016 Jun 11;95(7):1197-200. Epub 2016 Apr 11.

Department of Pathology, Brady Memorial Laboratory, Yale School of Medicine, 310 Cedar Street, New Haven, CT, 06510, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2664-4DOI Listing
June 2016

The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.

Expert Rev Anticancer Ther 2015 17;15(9):1019-36. Epub 2015 Aug 17.

a 1 Division of Hematology Oncology, Mount Sinai Beth Israel, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2015.1061936DOI Listing
May 2016

Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.

Cancer 2016 05 11;122(10):1598-607. Epub 2016 Mar 11.

Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29945DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509410PMC
May 2016

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.

Blood Rev 2016 Jan 19;30(1):1-10. Epub 2015 Jun 19.

Section of Hematology, Department of Internal Medicine, Yale University, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2015.06.004DOI Listing
January 2016

Economic burden associated with acute myeloid leukemia treatment.

Expert Rev Hematol 2016 Jan 14;9(1):79-89. Epub 2015 Nov 14.

d Kimmel Cancer Center , Johns Hopkins , Baltimore , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2016.1112735DOI Listing
January 2016

Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.

Clin Lymphoma Myeloma Leuk 2015 Nov 2;15(11):705-10. Epub 2015 Sep 2.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.08.083DOI Listing
November 2015

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Oncologist 2015 Sep 20;20(9):1069-76. Epub 2015 Jul 20.

Section of Hematology, Department of Internal Medicine, Yale University and Yale Comprehensive Cancer Center, New Haven, Connecticut, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571815PMC
September 2015

Leukaemic vasculitis with myelodysplastic syndrome.

Lancet 2015 Aug;386(9992):501-2

Department of Dermatology, Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)61165-5DOI Listing
August 2015

Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

J Comp Eff Res 2015 Aug;4(4):327-40

Department of Health Policy & Management, Yale School of Public Health, Yale University, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer.15.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549705PMC
August 2015

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.

Semin Hematol 2015 Jul 8;52(3):172-83. Epub 2015 Apr 8.

Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, and Smilow Cancer Hospital at Yale-New Haven Hospital, New Haven, CT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2015.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785931PMC
July 2015

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?

Expert Rev Hematol 2015 Apr 19;8(2):155-8. Epub 2015 Feb 19.

Section of Hematology, Department of Internal Medicine, Yale University, 333 Cedar Street, PO Box 208028, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2015.1016905DOI Listing
April 2015

Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.

J Oncol Pract 2015 Mar 6;11(2):e190-8. Epub 2015 Jan 6.

Yale School of Public Health, Yale University; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Maryland School of Pharmacy; Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD; and US Health Outcomes and Medical Policy, GlaxoSmithKline, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2014.001527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371123PMC
March 2015

Current state of prognostication and risk stratification in myelodysplastic syndromes.

Curr Opin Hematol 2015 Mar;22(2):146-54

aSection of Hematology, Department of Internal Medicine, Yale University, New Haven, Connecticut bDepartment of Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000110DOI Listing
March 2015

Eliminating Health Care Disparities With Mandatory Clinical Decision Support: The Venous Thromboembolism (VTE) Example.

Med Care 2015 Jan;53(1):18-24

*Department of Surgery, Division of Acute Care Surgery, The Johns Hopkins University School of Medicine †The Armstrong Institute for Patient Safety, Johns Hopkins Medicine ‡Division of Health Sciences Informatics §Department of Anesthesiology & Critical Care Medicine ∥Department of Surgery, Center for Surgical Trials and Outcomes Research (CSTOR), The Johns Hopkins University School of Medicine ¶Department of Health Policy and Management, The Johns Hopkins University Bloomberg School of Public Health #Department of Medicine, Division of Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD **Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Vanderbilt University School of Medicine, Nashville, TN ††Department of Pharmacy, The Johns Hopkins Hospital ‡‡Section of Hematology, Department of Internal Medicine, Yale University, New Haven, CT §§Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MLR.0000000000000251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262632PMC
January 2015

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.

J Blood Med 2015 22;6:1-16. Epub 2014 Dec 22.

Division of Hematology, Department of Medicine, Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JBM.S50482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278786PMC
January 2015

Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies.

Gynecol Oncol 2014 Oct 27;135(1):163-71. Epub 2014 Jul 27.

Section of Hematology, Department of Internal Medicine, Yale University, and Yale Cancer Center, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.07.095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404750PMC
October 2014